Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for unmet medical needs across oncology supportive care, mast-cell disorders, neuroinflammation, dermatology, respiratory disease, and obesity-related conditions. The company has not commercialized any products and is still funding preclinical and clinical development of candidates such as HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, and HT-VA.

2

4.72

4.30

— Hoth Therapeutics, Inc.
%
Oncology supportive care25% Therapies intended to reduce side effects from cancer treatments, centered on HT-001.
Rare disease and immunology35% Programs targeting mast-cell cancers, anaphylaxis, eczema, asthma, and allergies.
Neuroinflammation and CNS20% Development-stage assets aimed at Alzheimer’s disease and related neuroinflammatory conditions.
Metabolic disease20% Obesity and obesity-related disease programs, primarily HT-VA.

Hoth Therapeutics does not yet sell commercial products, so its current “customers” are primarily research partners,...

  • Future patients and prescribersprimary

    Would use HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, or HT-VA if approved; demand is driven by unmet medical need.

  • Clinical investigators and trial sitesprimary

    Run studies for the company’s pipeline and generate the data needed for regulatory advancement.

  • Licensing and research partnerssecondary

    Provide sponsored research, option, sublicense, or collaboration support and may fund development.

  • Institutional and retail capital marketsprimary

    Provide equity and debt financing because the company has no product revenue and ongoing cash burn.

Hoth Therapeutics is based in the United States and its reported disclosures are U.S.-centric, including reimbursement,...

  • •Headquartered in the United States
  • •Clinical and regulatory exposure is primarily U.S.-based
  • •No product sales revenue disclosed to date
  • •Future commercialization would depend on U.S. payer coverage
  • •No country-level revenue breakdown disclosed

The company’s strategy is to advance a diversified pipeline of early-stage assets across several therapeutic areas...

01
Advance lead pipeline assets through development milestonesshort-term

Clinical proof is the main driver of valuation and partnering interest for a pre-revenue biotech.

02
Secure external financing and strategic partnershipsshort-term

The company has no product revenue and ongoing operating losses, so funding is required to continue development.

03
Broaden optionality across multiple therapeutic areasmedium-term

A multi-asset pipeline reduces dependence on any single program and increases the chance of a value-creating outcome.

Hoth Therapeutics is exposed to the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and...

critical

No product commercialization

The company has never generated revenue from product sales, so it depends on capital markets and development success.

Scope
Entire business model
Materiality
high
high

Clinical and regulatory failure

Pipeline assets are preclinical/clinical-stage and may not demonstrate safety or efficacy.

Scope
HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, HT-VA
Materiality
high
high

Financing and dilution risk

The company has recurring operating losses and will need additional funding to continue development.

Scope
Equity issuance, debt, warrants
Materiality
high
medium

Reimbursement and pricing pressure

Medicare and private payor policies can reduce future pricing and coverage for approved drugs.

Scope
Future U.S. commercialization
Materiality
medium
medium

Contractual milestone and royalty obligations

License and sponsored research agreements may require milestone, royalty, and maintenance payments.

Scope
Future cash flows
Materiality
medium
Stock-based compensation
Reported operating loss and EPS
Fair value of warrants and equity instruments
Capital structure and dilution
Going-concern and liquidity assessment
Disclosure and investor risk assessment
License and milestone obligations
Future cash outflows and contingent liabilities

: 28.4.2026